Company Description
Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform.
It operates through two segments, Beyond Air and Beyond Cancer. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn.
It is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria.
In addition, the company develops ultra-high concentration NO in Phase 1 clinical trial to treat solid tumors.
It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions.
The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019.
Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York.
| Country | United States |
| Founded | 2011 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 107 |
| CEO | Steven Lisi |
Contact Details
Address: 900 Stewart Avenue, Suite 301 Garden City, New York 11530 United States | |
| Phone | 516 665 8200 |
| Website | beyondair.net |
Stock Details
| Ticker Symbol | XAIR |
| Exchange | NASDAQ |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0001641631 |
| CUSIP Number | 08862L103 |
| ISIN Number | US08862L1035 |
| Employer ID | 47-3812456 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Amir Avniel | Chief Executive Officer of NeuroNOS |
| Steven Adam Lisi | Chief Executive Officer and Chairman of the Board |
| Michael A. Gaul | Chief Operating Officer |
| Douglas Quinton Larson | Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer |
| Edward Barger | Head of Investor Relations |
| Dr. Andrew R. Colin M.D. | Senior Medical Director Global Clinical Leadership and Member of Scientific Advisory Board |
| David R. Webster | Chief Commercial Officer |
| Dr. John Jett Ph.D. | Head of Research and Clinical Development |
| Adam Newman | Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 26, 2024 | EFFECT | Notice of Effectiveness |
| Nov 26, 2024 | 424B3 | Prospectus |
| Nov 26, 2024 | 8-K | Current Report |
| Nov 21, 2024 | S-3/A | [Amend] Registration statement under Securities Act of 1933 |
| Nov 18, 2024 | 8-K | Current Report |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 6, 2024 | 8-K | Current Report |
| Oct 31, 2024 | DEF 14A | Other definitive proxy statements |
| Oct 25, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Oct 18, 2024 | PRE 14A | Other preliminary proxy statements |